C. E. Hubbard, A. M. Barrios / Bioorg. Med. Chem. Lett. 18 (2008) 679–681
681
120
100
80
60
40
20
0
References and notes
1. Stoker, A. W. J. Endocrinol. 2005, 185, 19.
2. Alonso, A.; Sasin, J.; Bottini, N.; Friedberg, I.; Friedberg,
I.; Osterman, A.; Godzik, A.; Hunter, T.; Dixon, J.;
Mustelin, T. Cell 2004, 117, 699.
3. Mustelin, T.; Rahmouni, S.; Bottini, N.; Alonso, A.
Immunol. Rev. 2003, 191, 139.
4. Mustelin, T.; Vang, T.; Bottini, N. Nat. Immunol. 2005, 5,
43.
5. Zhang, Z.-Y. Curr. Opin. Chem. Biol. 2001, 5, 416.
6. Bialy, L.; Waldmann, H. Angew. Chem. Int. Ed. 2005, 44,
3814.
7. Zhang, Z.-Y. Acc. Chem. Res. 2003, 36, 385.
8. Zhang, Z.-Y. Biochim. Biophys. Acta 2005, 1754, 100.
9. Han, J.; Kwon, M.; Cho, H. J. Biochem. Mol. Biol. 1998,
31, 135.
10. Schwarzer, D.; Zhang, Z.; Zheng, W.; Cole, P. A. J. Am.
Chem. Soc. 2006, 128, 4192.
11. Shen, K. Methods 2007, 42, 234.
-4
-2 10-5 0 100 2 10-5 4 10-5 6 10-5 8 10-5 1 10-4 1.2 10-4 1.4 10
[peptide], M
Figure 2. Inhibition of CD45 (r) and TCPTP (k) by Ac-TEGQ-Pmp-
QPQP-NH2.
12. Phan, J.; Lee, K.; Cherry, S.; Tropea, J. E.; Burke, T. R.,
Jr.; Waugh, D. S. Biochemistry 2003, 42, 13113.
13. Tolkatchev, D.; Shaykhutdinov, R.; Xu, P.; Plamondon,
J.; Watson, D. C.; Young, N. M.; Ni, F. Protein Sci. 2006,
15, 2381.
14. Glover, N. R.; Tracey, A. S. Biochem. Cell Biol. 2000, 78,
39.
15. Burke, T. R., Jr.; Ye, B.; Yan, X.; Wang, S.; Jia, Z.; Chen,
L.; Zhang, Z.-Y.; Barford, D. Biochemistry 1996, 35,
15989.
ability of the peptide to inhibit PTP activity was investi-
gated.28,29 As illustrated in Figure 2, the peptide is a
moderately potent inhibitor of CD45 with an IC50 value
near 100 lM. This inhibition is consistent with other
Pmp-based inhibitors that have been reported previ-
ously.16 Interestingly, another T-cell derived phospha-
tase, TCPTP, was not inhibited by the peptide at
concentrations up to 120 lM.
16. Chen, L.; Wu, L.; Otaka, A.; Smyth, M. S.; Roller, P. P.;
Burke, T. R.; Denhertog, J.; Zhang, Z.-Y. Biochem.
Biophys. Res. Commun. 1995, 216, 976.
17. Li, P.; Zhang, M.; Peach, M. L.; Liu, H.; Yang, D.; Roller,
P. P. Org. Lett. 2003, 5, 3095.
18. Cushman, M.; Lee, E.-S. Tetrahedron Lett. 1992, 33, 1193.
19. Liu, W.-Q.; Roques, B. P.; Garbay-Jaureguiberry, C.
Tetrahedron: Asymmetry 1995, 6, 647.
20. Garbay-Jaureguiberry, C.; McCort-Tranchepain, I.;
Barbe, B.; Ficheux, D.; Roques, B. P. Tetrahedron:
Asymmetry 1992, 3, 637.
In summary, we have achieved a facile, gram-scale syn-
thesis of Bz-Pmp from enantiomerically pure, readily
available starting materials in five steps with 67% overall
yield. As a proof-of-principle, Bz-Pmp has been incor-
porated into the peptide sequence Ac-TEGQ-Pmp-
QPQP-NH2, resulting in a moderately potent inhibitor
of CD45 activity. This gram-scale synthesis of Pmp will
facilitate future work on the importance of tyrosine
phosphorylation in biology by serving as a readily acces-
sible mimic of phosphotyrosine.
21. Yokomatsu, T.; Minowa, T.; Murano, T.; Shibuya, S.
Tetrahedron 1998, 54, 9341.
22. Baczko, K.; Liu, W.-Q.; Roques, B. P.; Garbay-Jauregui-
berry, C. Tetrahedron 1996, 52, 2021.
Acknowledgments
23. Marseigne, I.; Roques, B. P. J. Org. Chem. 1988, 53, 3621.
24. Arslan, T.; Mamaev, S. V.; Mamaeva, N. V.; Hecht, S. M.
J. Am. Chem. Soc. 1997, 119, 10877.
25. Yao, Z.-J.; Gao, Y.; Burke, T. R., Jr. Tetrahedron:
Asymmetry 1999, 10, 3727.
This work was supported in part by grants from the
Zumberge Research and Innovation Fund at USC, the
American Cancer Society (USC/Norris Cancer Center
IRG-58-007-48) and the National Institutes of Health
(R21 NS056945).
26. Meyer, F.; Laaziri, A.; Papini, A. M.; Uziel, J.; Juge, S.
Tetrahedron: Asymmetry 2003, 14, 2229.
27. Zhou, J.; Fu, G. C. J. Am. Chem. Soc. 2004, 126, 1340.
28. Gee, K. R.; Sun, W.-C.; Bhalgat, M. K.; Upson, R.;
Klaubert, D. H.; Latham, K. A.; Haugland, R. P. Anal.
Biochem. 1999, 273, 41.
Supporting Information Available
Supplementary data associated with this article can be
29. Welte, S.; Baringhaus, K.-H.; Schmider, W.; Muller,
G.; Petry, S.; Tennagels, N. Anal. Biochem. 2005, 338,
32.